

Unto Iva
Decreto Lei
N 197 2012
De 24 De
Agosto

**Unto Iva Decreto
Lei N**
Copenhagen,
Denmark; March

Page 1/11

30, 2021 –
Genmab A/S
(Nasdaq: GMAB)
announced today
that the European
Commission (EC)
has granted
Novartis marketing
authorization for
the use of
Kesimpta ®
(ofatumumab) in ...

Page 2/11

**Genmab
Announces
European
Marketing
Authorization for
Kesimpta®
(ofatumumab) in
Relapsing
Multiple Sclerosis**
President Biden
will announce that

Page 3/11

the target to make
COVID-19
vaccines available
to everyone age
16 and older will
be moved up by
nearly two weeks,
the White House
said, as the U.S.
has ...

Copenhagen,
Denmark; March 30,
2021 – Genmab A/S
(Nasdaq: GMAB)
announced today that
the European
Commission (EC) has
granted Novartis
marketing
authorization for the
use of Kesimpta ®
(ofatumumab) in ...

President Biden will announce that the target to make COVID-19 vaccines available to everyone age 16 and older will be moved up by nearly two weeks, the White House said, as the U.S. has ...

Unto Iva Decreto Lei
N

**Genmab Announces
European
Marketing
Authorization
for Kesimpta®
(ofatumumab) in
Relapsing
Multiple
Sclerosis**

Unto Iva

Page 7/11

unto-iva-decreto-lei-n-197-2012-de-24-de-agosto

Decreto Lei N
Copenhagen,
Denmark; March
30, 2021 -
Genmab A/S
(Nasdaq: GMAB)
announced
today that the
European
Commission
(EC) has
granted

Page 8/11

Novartis
marketing
authorization
for the use of
Kesimpta ®
(ofatumumab)
in ...

Genmab
Announces
European
Marketing

Page 9/11

**Authorization
for Kesimpta®
(ofatumumab)
in Relapsing
Multiple
Sclerosis**

President
Biden will
announce that
the target to
make COVID-19
vaccines

Page 10/11

available to everyone age 16 and older will be moved up by nearly two weeks, the White House said, as the U.S. has ...